AIM:To assess the effect of topical bevacizumab use on postoperative pterygium recurrence in eyes who underwent pterygium excision with limbal-conjunctival autograft transplantation(LCAT).METHODS:eighty-eight eyes of ...AIM:To assess the effect of topical bevacizumab use on postoperative pterygium recurrence in eyes who underwent pterygium excision with limbal-conjunctival autograft transplantation(LCAT).METHODS:eighty-eight eyes of 88 patients with primary pterygium were included.Pterygia were graded preoperatively from type 1 to type 3(type 1 atrophic,type3 inflamed)according to the inflammatory status.The eyes were preoperatively randomized to receive topical steroid and antibiotic treatment(group 1,46 eyes)and additional topical bevacizumab(5 mg/mL;group 2,42eyes)in the postoperative period.All eyes underwent pterygium excision and LCAT.Medications were tapered and discontinued at one month.Postoperative complications and recurrence rates were recorded.RESULTS:The mean follow-up duration was 29.3±4.2mo(24-52mo)and 28.5±3.4(24-48mo)in group 1 and2,respectively(P】0.05).There were no statistically significant differences regarding the age or gender between groups(P】0.05).Also,the difference between groups with respect to pterygium type was not significant.During the follow-up period,recurrence developed in 2 eyes(4.3%)in group 1,whereas in one eye(2.4%)in group 2.No statistically significant difference between groups was found in recurrence rates(P】0.05).No re-operation for recurrence was necessary during the follow-up period in both groups.CONCLUSION:Topical bevacizumab seems to have no additonal effect on pterygium recurrence after LCAT.展开更多
Background:The study aimed to evaluate the efficacy of postoperative short-term therapy(for 2 weeks)of topical bevacizumab in recurrent pterygium surgery regarding to corneal vascularization and pterygium recurrence.M...Background:The study aimed to evaluate the efficacy of postoperative short-term therapy(for 2 weeks)of topical bevacizumab in recurrent pterygium surgery regarding to corneal vascularization and pterygium recurrence.Methods:This prospective randomized comparative study included two groups of patients with recurrent pterygium,all eyes were subjected to pterygium excision with conjunctiva auto graft,and group A(30 eyes of 30 patients)was treated with postoperative topical tobramycine and dexamethazone for 2 weeks.Group B(30 eyes of 30 patients)was treated also with postoperative topical tobramycine and dexamethazone in addition to topical bevacizumab 5 mg/mL 4 times daily for 2 weeks.Follow-up of cases up to 6 months was performed recording corneal vascularization and pterygium recurrence.Results:The results revealed that after 6 months,group A treated with postoperative tobramycine and dexamethazone reported 5 eyes of recurrence(16.7%)which not significantly(P=0.44726)(P>0.05)different from group B treated with the addition of topical bevacizumab which reported 3 eyes of recurrence(10%).But group B showed significantly different in decreasing corneal neovascularization than group A(P=0.000805)(P<0.05).Conclusions:Postoperative short-term therapy of topical bevacizumab in recurrent pterygium surgery by conjunctiva auto graft showed lower recurrence rate but not statistically significant,But it reduced significantly corneal neovascularization.展开更多
文摘AIM:To assess the effect of topical bevacizumab use on postoperative pterygium recurrence in eyes who underwent pterygium excision with limbal-conjunctival autograft transplantation(LCAT).METHODS:eighty-eight eyes of 88 patients with primary pterygium were included.Pterygia were graded preoperatively from type 1 to type 3(type 1 atrophic,type3 inflamed)according to the inflammatory status.The eyes were preoperatively randomized to receive topical steroid and antibiotic treatment(group 1,46 eyes)and additional topical bevacizumab(5 mg/mL;group 2,42eyes)in the postoperative period.All eyes underwent pterygium excision and LCAT.Medications were tapered and discontinued at one month.Postoperative complications and recurrence rates were recorded.RESULTS:The mean follow-up duration was 29.3±4.2mo(24-52mo)and 28.5±3.4(24-48mo)in group 1 and2,respectively(P】0.05).There were no statistically significant differences regarding the age or gender between groups(P】0.05).Also,the difference between groups with respect to pterygium type was not significant.During the follow-up period,recurrence developed in 2 eyes(4.3%)in group 1,whereas in one eye(2.4%)in group 2.No statistically significant difference between groups was found in recurrence rates(P】0.05).No re-operation for recurrence was necessary during the follow-up period in both groups.CONCLUSION:Topical bevacizumab seems to have no additonal effect on pterygium recurrence after LCAT.
文摘Background:The study aimed to evaluate the efficacy of postoperative short-term therapy(for 2 weeks)of topical bevacizumab in recurrent pterygium surgery regarding to corneal vascularization and pterygium recurrence.Methods:This prospective randomized comparative study included two groups of patients with recurrent pterygium,all eyes were subjected to pterygium excision with conjunctiva auto graft,and group A(30 eyes of 30 patients)was treated with postoperative topical tobramycine and dexamethazone for 2 weeks.Group B(30 eyes of 30 patients)was treated also with postoperative topical tobramycine and dexamethazone in addition to topical bevacizumab 5 mg/mL 4 times daily for 2 weeks.Follow-up of cases up to 6 months was performed recording corneal vascularization and pterygium recurrence.Results:The results revealed that after 6 months,group A treated with postoperative tobramycine and dexamethazone reported 5 eyes of recurrence(16.7%)which not significantly(P=0.44726)(P>0.05)different from group B treated with the addition of topical bevacizumab which reported 3 eyes of recurrence(10%).But group B showed significantly different in decreasing corneal neovascularization than group A(P=0.000805)(P<0.05).Conclusions:Postoperative short-term therapy of topical bevacizumab in recurrent pterygium surgery by conjunctiva auto graft showed lower recurrence rate but not statistically significant,But it reduced significantly corneal neovascularization.
